Biotech: Page 22
-
Permission granted by TRex Bio
TRex Bio raises $84M to compete in crowded immune drug field
The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.
By Gwendolyn Wu • Nov. 13, 2024 -
Thomas Lohnes via Getty Images
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab.
By Jonathan Gardner • Nov. 13, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Permission granted by Flagship Pioneering
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for Parkinson’s and another neurodegenerative condition.
By Gwendolyn Wu • Nov. 12, 2024 -
Getty Images
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.
By Jacob Bell • Nov. 12, 2024 -
Getty Images
FDA approves new CAR-T competitor to Gilead’s Tecartus
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the brand name Aucatzyl.
By Jonathan Gardner • Nov. 11, 2024 -
Sarah Silbiger via Getty Images
FDA lifts pause on Novavax flu vaccine trials
After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and unrelated to vaccination.
By Delilah Alvarado • Nov. 11, 2024 -
Permission granted by Cullinan Therapeutics
Sponsored by Cullinan TherapeuticsFueling accelerated drug development in autoimmune diseases with a modality-agnostic approach
Innovation-without-borders philosophy seeks to bring forward only the most promising therapies.
By Cullinan Therapeutics • Nov. 11, 2024 -
Shutterstock/Ad_hominem
Sponsored by LabConnect7 steps to selecting the right global central lab
Unlock global clinical trial success with seamless sample logistics and standardized testing.
Nov. 11, 2024 -
Getty Images
Kalaris to go public via reverse merger with AlloVir
After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
By Delilah Alvarado • Updated Nov. 8, 2024 -
Getty Images
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a narcolepsy drug and CDMO Avid Bioservices agreed to be taken private.
By BioPharma Dive staff • Nov. 8, 2024 -
Getty Images
Athira exploring strategic alternatives after Alzheimer’s failure
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could take to “maximizing stockholder value.”
By Jacob Bell • Nov. 8, 2024 -
Jacob Bell/BioPharma Dive
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
By Ned Pagliarulo • Nov. 7, 2024 -
Jacob Bell/BioPharma Dive
Sarepta scraps a Duchenne drug as gene therapy sales rise
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
By Kristin Jensen • Nov. 7, 2024 -
Chip Somodevilla via Getty Images
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change at the FTC could lower M&A scrutiny.
By Ned Pagliarulo , Ben Fidler • Nov. 7, 2024 -
Getty Images
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ambitious sales target and Syndax inked a lucrative royalty deal.
By BioPharma Dive staff • Nov. 6, 2024 -
Jacob Bell/BioPharma Dive
Emerging biotechAn RNAi renaissance is creating a new generation of startups
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
By Gwendolyn Wu • Nov. 6, 2024 -
Peddalanka Ramesh Babu via Getty Images
Cancer cell therapy from Arcellx, Gilead shows promise in early data
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare.
By Jonathan Gardner • Nov. 5, 2024 -
Getty Images
Sickle cell patient dies in Beam study of base editing therapy
The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.
By Ned Pagliarulo • Nov. 5, 2024 -
Permission granted by Rallybio
Two former Alexion leaders fight through a tough market to sustain a rare disease biotech
Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech's down market has made the company's journey difficult.
By Michael Gibney • Nov. 5, 2024 -
Getty Images
Neurogene secures $200M ahead of anticipated study readout
The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett syndrome may turn out positive.
By Delilah Alvarado • Nov. 4, 2024 -
Getty Images
Sponsored by CognizantCenters of excellence or product-centric BizDevOps managed services?
As novel therapeutics become more complex — and costly — to bring to market, drug developers are looking to unified clinical development platforms to streamline operations.
Nov. 4, 2024 -
ShutterStock/Chepko Danil Vitalevich
Sponsored by Bio-RadEmpowering versatile applications of digital PCR with standardized, validated assays
Bio-Rad’s extensive ddPCR assay offerings help researchers leverage the full power of digital PCR.
Nov. 4, 2024 -
Getty Images
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck’s Longboard buyout and PTC continued a quixotic quest.
By BioPharma Dive staff • Nov. 1, 2024 -
Spencer Platt via Getty Images
Jade, another biotech spinout of Paragon, to merge with Aerovate
The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate.
By Ned Pagliarulo • Oct. 31, 2024 -
Getty Images
Compass delays anticipated psilocybin readout, cuts staff
The company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders.
By Kristin Jensen • Oct. 31, 2024
Previous
